Clinical Trial

Bioequivalence Study of Trifluridine and Tipiracil Hydrochloride Tablets on Fasting and Fed in Humans

Name: Bioequivalence Study of Trifluridine and Tipiracil Hydrochloride Tablets on Fasting and Fed in Humans — clinical trial record (NCT07492173)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Completed

View on ClinicalTrials.gov →

Summary

The test formulation of Trifluridine and Tipiracil Tablets (20 mg) is bioequivalent to the reference formulation (Lonsurf®) in Chinese patients with solid tumors under fed and fasting conditions.

Trial Details

NCT Number	NCT07492173
Lead Sponsor	Shandong New Time Pharmaceutical Co., LTD
Conditions	Solid Tumor Cancer
Enrollment	76 participants
Start Date	2022-11-21
Primary Completion	2023-06-25 (estimated)
Study Completion	2023-06-25 (estimated)
Updated on ClinicalTrials.gov	2026-03-25